Insmed Investor Relations Material
Latest events
Status Update
Insmed
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Insmed Incorporated
Access all reports
Insmed Incorporated is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for patients living with serious and rare diseases. The Company's marketed product ARIKAYCE, or L-Amikacin, is approved in the United States for the treatment of Mycobacterium avium complex lung disease as part of a combination anti-mycobacterial drug regimen for adult patients who are refractory to or intolerant of conventional treatments.
Key slides for Insmed Incorporated
Q4 2023
Insmed Incorporated
Status Update
Insmed Incorporated
Latest articles
The Birkin Bag: The Story Behind the World's Most Desired Handbag
How the Birkin bag became the world's most sought-after handbag where even the wealthy must earn the right to own one.
12 Jul 2024
The 10 Largest Semiconductor Companies in the World
Discover the top 10 semiconductor companies by market cap, exploring their innovations and business models shaping the tech landscape.
10 Jul 2024
The Rise of Nubank: Changing Latin American Finance
Discover how Nubank revolutionized Latin American banking with innovation, backed by top investors like Berkshire Hathaway.
9 Jul 2024
Ticker symbol
INSM
Country
🇺🇸 United States